N-Acetyltransferase 2 genetic polymorphisms and risk of colorectal cancer

Table 2 Distribution of N-acetyltransferase 2 polymorphism and the risk of cancer

Genetic polymorphism NAT2a	Cancer, n (%)	Control, n (%)	P	OR (95% CI)
All	147	212
Mx/Mx	88 (59.8)	110 (51.9)	0.19	1
W/Mx	44 (30.0)	83 (39.1)		0.66 (0.42-1.05)
W/W	15 (10.2)	19 (8.9)		0.99 (0.47-2.05)
Slow	88 (59.8)	110 (51.9)	0.17	1.38 (0-2.12)
Fast	59 (40.1)	102 (48.1)
Female	76	127
Mx/Mx	42 (55.2)	58 (45.6)	0.07	1
W/Mx	23 (30.2)	58 (45.6)		0.55 (0.29-1.02)
W/W	11 (14.4)	11 (8.6)		1.38 (0.55-3.48)
Slow	42 (55.2)	58 (45.6)	0.24	1.47 (0.83-2.60)
Fast	34 (44.7)	69 (54.3)
Male	71	85
Mx/Mx	46 (64.8)	52 (61.1)	0.67	1
W/Mx	21 (29.5)	25 (29.4)		0.95 (0.47-1.92)
W/W	4 (5.6)	8 (9.4)		0.57 (0.16-2.00)
Slow	46 (64.7)	52 (61.1)	0.76	0.86 (0.45-1.65)
Fast	25 (35.2)	33 (38.9)

^aHomozygous individuals with genotype W/W, and heterozygote W/Mx, are grouped into fast acetylation phenotype, while homozygous Mx/Mx are grouped in slow acetylators. The percentages of data are in parentheses. NAT2: N-acetyltransferase 2; OR: Odds ratio; 95% CI: Confidence interval.